Pre-made Lirentelimab benchmark antibody ( Whole mAb, anti-SIGLEC8/Siglec-8 therapeutic antibody, Anti-SAF2 Antibody) for drug discovery and mechanism of action (MOA) research

Pre-Made Lirentelimab biosimilar, Whole mAb, Anti-SIGLEC8/Siglec-8 Antibody: Anti-SAF2 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Lirentelimab (sold under the brand name AK002) is a humanized nonfucosylated monoclonal antibody that targets sialic acid-binding Ig-like lectin 8 (SIGLEC8). In a randomized clinical trial, lirentelimab was found to improve eosinophil counts and symptoms in individuals with eosinophilic gastritis and duodenitis. Adverse reactions include infusion reactions, which are mild to moderate and typically occur following the first infusion.

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	Price(In USD)	Qty (Quantity)	Sum(In USD)
GMP-Bios-ab-315-1mg	1mg	3090
GMP-Bios-ab-315-10mg	10mg	Inquiry
GMP-Bios-ab-315-100mg	100mg	Inquiry
GMP-Bios-ab-315-xmg	≥100mg	Inquiry
			Shipping Cost:	760.00
			Total:

Description

Products Name (INN Index)	Pre-Made Lirentelimab biosimilar, Whole mAb, Anti-SIGLEC8/Siglec-8 Antibody: Anti-SAF2 therapeutic antibody
INN Name	Lirentelimab
Target	SIGLEC8
Format	Whole mAb
Derivation
Species Reactivity	Human
CH1 Isotype	IgG1
VD LC	Kappa
Highest_Clin_Trial (Jan '20)	Phase-III
Est. Status	Active
100% SI Structure	None
99% SI Structure	None
95-98% SI Structure	None
Year Proposed	2020
Year Recommended	na
Companies	Allakos
Conditions Approved	na
Conditions Active	Eosinophilic gastroenteritis;Eosinophilic oesophagitis;Urticari;Atopic dermatitis;Chronic obstructive pulmonary disease
Conditions Discontinued	Conjunctiviti;Fibrosis;Kertoconjunctivitis;Systemic mastocytosis
Development Tech	na